Market Watch column provides a thorough analysis of stock market fluctuations and expert ratings.

Bristol-Myers Squibb Ranks 77th in Trading Volume with $995 Million as Q1 Revenue Surges to $11.2 Billion

Market BriefThursday, Apr 24, 2025 7:45 pm ET

1min read

On April 24, 2025, Bristol-Myers Squibb (BMY) closed with a trading volume of $995 million, ranking 77th in the day's stock market activity. The stock price increased by 0.33%.

Bristol-Myers Squibb reported a strong performance in the first quarter of 2025, transitioning from a net loss to a profit. The company's revenue for the quarter reached $11.2 billion, driven by an 18% growth in its portfolio. This significant increase was attributed to the equal contribution from both the growth and legacy portfolios, each generating $5.6 billion in revenue.

In response to these positive results, Bristol-Myers Squibb raised its full-year 2025 revenue guidance to a range of $45.8 billion to $46.8 billion. Additionally, the company increased its adjusted earnings per share guidance for the full year to a range of $6.70 to $7.00. This upward revision reflects the company's confidence in its financial performance and growth prospects for the remainder of the year.

The company's strong Q1 performance and revised guidance have been well-received by investors, contributing to the positive sentiment surrounding the stock. The increase in revenue and earnings guidance underscores Bristol-Myers Squibb's strategic initiatives and operational efficiencies, positioning the company for continued success in the pharmaceutical industry.

Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.